Can You Cure Erectile Dysfunction?

The magnitude of average increased effects with increased doses is small and often not clinically significant (e.g., a one or two point increase on the IIEF-EF). IIEF-EF data for trials of sildenafil, tadalafil, and vardenafil that used fixed doses are below (insufficient data for avanafil).

On demand dosing vs. daily dosing for tadalafil appears to produce the same level of efficacy.

• MUSE system usage
• Alprostadil urethral pellets
• Non-invasive suppository method
• Side effects of urethral meds
• Nausea and flushing risks
• Proper insertion technique
• Timing with sexual activity
• Effectiveness compared to pills
• Who is a good candidate
• Storage of medication
• Avoiding urinary retention

Note that daily dosing trials generally used lower doses than did on demand trials. Trials of sildenafil and avanafil used only on demand dosing. Data from trials that evaluated men from the general ED population are below.

5 Conclusion

AUA urges strict compliance with all government regulations and protocols for prescription and use of these substances. The physician is encouraged to carefully follow all available prescribing information about indications, contraindications, precautions and warnings. These guidelines and best practice statements are not in-tended to provide legal advice about use and misuse of these substances. Although guidelines are intended to encourage best practices and potentially encompass available technologies with sufficient data as of close of the literature review, they are necessarily time-limited. Guidelines cannot include evaluation of all data on emerging technologies or management, including those that are FDA-approved, which may immediately come to represent accepted clinical practices.

Specific laboratory tests may be performed to determine the cause of erectile dysfunction including:

For this reason, the AUA does not regard technologies or management which are too new to be addressed by this guideline as necessarily experimental or investigational. Erectile dysfunction doesn’t need to control your life. Positive lifestyle changes can help to reduce your risk and erectile dysfunction treatments are available to help restore your sex life. More than half of men aged 40 to 70 years experience some level of erectile dysfunction. There are a range of effective treatments that can help you take back control of your sexual function. Tadalafil was the only medication for which there were substantial on demand vs. daily dosing studies. Most AEs follow a dose-response pattern such that men in active treatment arms reported statistically significantly higher rates of AEs than did men in placebo arms and the percentage of men reporting a particular AE increased as dose increases. Within individual studies, however, the differences between dose groups were usually not statistically significantly different.

Data from studies of men in the general ED population that administered medications at fixed doses (i.e., did not allow the patient to titrate dose up or down) are below. When means for the general and four special populations (men with diabetes, with BPH/LUTS, post-RP, or post-RT) for which there are substantial data were examined, it appears that men post-RP and men post-RT reported substantially higher rates of AEs than did men in the general ED population. Whether men who have had prostate cancer treatment are more likely to experience AEs or are more likely to report AEs is not clear. Men post-RP reported higher rates of AEs in response to sildenafil than in response to other PDE5s. Men post-RT reported high rates of AEs across PDE5s and in placebo groups. The high rates of AEs reported by men in placebo groups suggest that men post-RT may have heightened sensitivity to body sensations and may have unmet needs for psychosocial support.

Helping Your Partner with Erectile Dysfunction

Within individual studies, however, the differences between dose groups were usually not statistically significantly different. Data from studies of men in the general ED population that administered medications at fixed doses (i.e., did not allow the patient to titrate dose up or down) are below. When means for the general and four special populations (men with diabetes, with BPH/LUTS, post-RP, or post-RT) for which there are substantial data were examined, it appears that men post-RP and men post-RT reported substantially higher rates of AEs than did men in the general ED population. Whether men who have had prostate cancer treatment are more likely to experience AEs or are more likely to report AEs is not clear. Men post-RP reported higher rates of AEs in response to sildenafil than in response to other PDE5s.

Surgical Treatment

Men post-RT reported high rates of AEs across PDE5s and in placebo groups. The high rates of AEs reported by men in placebo groups suggest that men post-RT may have heightened sensitivity to body sensations and may have unmet needs for psychosocial support. These patterns can be seen in the table below (AEs for which there were 1 or 2 study arms are omitted); see cells in bold. Appendix B2 – Guideline Statement 16: Intracavernosal injection (ICI) data Commonly reported adverse events in extracted ICI studies: Appendix B3– Guideline Statement 18: Penile prosthesis data Patient and partner satisfaction data: Appendix B4 – Guideline Statement 21: Penile arterial reconstruction data Complete, partial, and non-response rates to surgery: Below are those data; for studies that reported response rates at different durations post-surgery, the latest duration was used. Appendix B5 – Guideline Statement 22: Penile venous surgery data Complete, partial, and non-response rates to surgery: The pattern of declining positive response rates over time can be seen in the scatterplot below which plots complete and partial responder rates by follow-up duration. These patterns can be seen in the table below (AEs for which there were 1 or 2 study arms are omitted); see cells in bold. Appendix B2 – Guideline Statement 16: Intracavernosal injection (ICI) data Commonly reported adverse events in extracted ICI studies: Appendix B3– Guideline Statement 18: Penile prosthesis data Patient and partner satisfaction data: Appendix B4 – Guideline Statement 21: Penile arterial reconstruction data Complete, partial, and non-response rates to surgery: Below are those data; for studies that reported response rates at different durations post-surgery, the latest duration was used. Appendix B5 – Guideline Statement 22: Penile venous surgery data Complete, partial, and non-response rates to surgery: The pattern of declining positive response rates over time can be seen in the scatterplot below which plots complete and partial responder rates by follow-up duration.

Organic Erectile Dysfunction

These include medications, intraurethral suppositories, penile injections, and a penile implant. Read more about these treatments below and talk with your urologist to find the right impotence treatment for you. Erectile dysfunction (ED), formerly termed impotence, is defined as "the inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance" or "the consistent or recurrent inability to attain and/or maintain penile erection sufficient for sexual satisfaction". [1] Although some cases, particularly in younger men, may primarily reflect psychological concerns, in many cases ED results from organic disease—notably, cardiovascular disease, diabetes mellitus, hyperlipidemia, and hypertension. [2] Thus, ED may serve as a marker for medical conditions in need of treatment.

3.5 Dual-energy CT arteriography (D-e CTA)

[1] Regardless of the cause, however, ED can have negative effects on patients' self-esteem, relationships, and overall quality of life. The first step in the management of ED is a thorough history that includes the following: A physical examination is necessary for every patient, emphasizing the genitourinary, vascular, and neurologic systems. A focused examination entails evaluation of the following: Presence of the epididymis and vas deferens Abnormalities of the penis (eg, hypospadias, Peyronie plaques) There is a strong correlation between hypertension and ED. There is also a correlation between benign prostatic hyperplasia and ED, though the causality is unclear. Laboratory testing for ED depends on information gathered during the interview; it is necessary for most patients, although not for all. The exception to this trend is Hsu, Chen (2010) who reported that 85.6% of 167 Taiwanese men at 92.4 mos of follow-up were complete responders to venous ligation surgery[926]. These men had no comorbidities at the time of surgery. The procedure involved stripping and ligation of the deep dorsal, emissary, and cavernosal veins as well as ligation of the para-arterial veins; some men also had ligation of the crural veins. Overall, there was considerable variability regarding response rates. Below are those data; for studies that reported response rates at different durations post-surgery, the latest duration was used.

Related Links

The exception to this trend is Hsu, Chen (2010) who reported that 85.6% of 167 Taiwanese men at 92.4 mos of follow-up were complete responders to venous ligation surgery[926]. These men had no comorbidities at the time of surgery. The procedure involved stripping and ligation of the deep dorsal, emissary, and cavernosal veins as well as ligation of the para-arterial veins; some men also had ligation of the crural veins. Overall, there was considerable variability regarding response rates. Below are those data; for studies that reported response rates at different durations post-surgery, the latest duration was used.

Causes of ED

This document was written by the Erectile Dysfunction Guideline Panel of the American Urological Association Education and Research, Inc., which was created in 2016. The Practice Guidelines Committee (PGC) of the AUA selected the committee chair. Panel members were selected by the chair. Membership of the Panel included specialists in urology, family medicine, and psychology with specific expertise on this disorder. The mission of the Panel was to develop recommendations that are analysis-based or consensus-based, depending on Panel processes and available data, for optimal clinical practices in the treatment of muscle-invasive bladder cancer. This document was written by the Erectile Dysfunction Guideline Panel of the American Urological Association Education and Research, Inc., which was created in 2016. The Practice Guidelines Committee (PGC) of the AUA selected the committee chair. Panel members were selected by the chair. Membership of the Panel included specialists in urology, family medicine, and psychology with specific expertise on this disorder. The mission of the Panel was to develop recommendations that are analysis-based or consensus-based, depending on Panel processes and available data, for optimal clinical practices in the treatment of muscle-invasive bladder cancer. Funding of the Panel was provided by the AUA. Panel members received no remuneration for their work. Each member of the Panel provides an ongoing conflict of interest disclosure to the AUA. While these guidelines do not necessarily establish the standard of care, AUA seeks to recommend and to encourage compliance by practitioners with current best practices related to the condition being treated. As medical knowledge expands and technology advances, the guidelines will change. Today these evidence-based guidelines statements represent not absolute mandates but provisional proposals for treatment under the specific conditions described in each document. For all these reasons, the guidelines do not pre-empt physician sex tablet 100mg judgment in individual cases.

When to See a Doctor

Evaluation of hormonal status (testosterone, serum hormone–binding globulin, luteinizing hormone [LH], prolactin, thyroid-stimulating hormone [TSH]) – Note that the American College of Physicians (ACP) does not recommend for or against routine use of hormonal blood tests or hormonal treatment in ED patients Evaluation of hormonal status (testosterone, serum hormone–binding globulin, luteinizing hormone [LH], prolactin, thyroid-stimulating hormone [TSH]) – Note that the American College of Physicians (ACP) does not recommend for or against routine use of hormonal blood tests or hormonal treatment in ED patients Screening blood studies (hemoglobin A1c, serum chemistry panel, lipid profile) Screening blood studies (hemoglobin A1c, serum chemistry panel, lipid profile) Prostate-specific antigen levels, if the patient is a candidate for prostate cancer screening (controversial) Prostate-specific antigen levels, if the patient is a candidate for prostate cancer screening (controversial) Functional tests that may be helpful include the following: Direct injection of prostaglandin E1 (PGE1; alprostadil) into the corpora cavernosa (see the image below) Direct injection of prostaglandin E1 (PGE1; alprostadil) into the corpora cavernosa (see the image below) Nocturnal penile tumescence testing – Once frequently performed, this is rarely used in current practice, though it can be helpful when the diagnosis is in doubt Nocturnal penile tumescence testing – Once frequently performed, this is rarely used in current practice, though it can be helpful when the diagnosis is in doubt Formal neurologic testing – Not needed in the vast majority of ED patients, though it may offer some benefit to patients with a history of central nervous system problems, peripheral neuropathy, diabetes, or penile sensory deficit Formal neurologic testing – Not needed in the vast majority of ED patients, though it may offer some benefit to patients with a history of central nervous system problems, peripheral neuropathy, diabetes, or penile sensory deficit Imaging studies are not commonly warranted, except in situations where pelvic trauma has been sustained or surgery performed. Treating physicians must take into account variations in resources, and patient tolerances, needs, and preferences. Conformance with any clinical guideline does not guarantee a successful outcome. The guideline text may include information or recommendations about certain drug uses ('off label') that are not approved by the Food and Drug Administration (FDA), or about medications or substances not subject to the FDA approval process.

AUA urges strict compliance with all government regulations and protocols for prescription and use of these substances. The physician is encouraged to carefully follow all available prescribing information about indications, contraindications, precautions and warnings.

Journal Articles References and abstracts from MEDLINE/PubMed (National Library of Medicine)

Funding of the Panel was provided by the AUA. Panel members received no remuneration for their work. Each member of the Panel provides an ongoing conflict of interest disclosure to the AUA. While these guidelines do not necessarily establish the standard of care, AUA seeks to recommend and to encourage compliance by practitioners with current best practices related to the condition being treated. As medical knowledge expands and technology advances, the guidelines will change.

Hormonal optimization

Today these evidence-based guidelines statements represent not absolute mandates but provisional proposals for treatment under the specific conditions described in each document. For all these reasons, the guidelines do not pre-empt physician sex tablet 100mg judgment in individual cases. Treating physicians must take into account variations in resources, and patient tolerances, needs, and preferences. Conformance with any clinical guideline does not guarantee a successful outcome. The guideline text may include information or recommendations about certain drug uses ('off label') that are not approved by the Food and Drug Administration (FDA), or about medications or substances not subject to the FDA approval process. These guidelines and best practice statements are not in-tended to provide legal advice about use and misuse of these substances. Although guidelines are intended to encourage best practices and potentially encompass available technologies with sufficient data as of close of the literature review, they are necessarily time-limited. Guidelines cannot include evaluation of all data on emerging technologies or management, including those that are FDA-approved, which may immediately come to represent accepted clinical practices. For this reason, the AUA does not regard technologies or management which are too new to be addressed by this guideline as necessarily experimental or investigational. Erectile dysfunction doesn’t need to control your life. Positive lifestyle changes can help to reduce your risk and erectile dysfunction treatments are available to help restore your sex life. More than half of men aged 40 to 70 years experience some level of erectile dysfunction.

• PDE5 inhibitors are effective but may cause side effects like headaches and flushing.
• Smoking cessation improves blood vessel health, enhancing erectile function.
• Weight management helps reduce the risk factors associated with ED.
• Pelvic floor exercises can strengthen muscles involved in erection and urination.
• Counseling may help men with ED related to psychological or emotional issues.
• Hormonal treatments are suitable for those with hormonal imbalances.
• Surgical interventions are typically reserved for cases unresponsive to other treatments.

There are a range of effective treatments that can help you take back control of your sexual function. These include medications, intraurethral suppositories, penile injections, and a penile implant.

Preventing Erectile Dysfunction

The magnitude of average increased effects with increased doses is small and often not clinically significant (e.g., a one or two point increase on the IIEF-EF). IIEF-EF data for trials of sildenafil, tadalafil, and vardenafil that used fixed doses are below (insufficient data for avanafil). On demand dosing vs. daily dosing for tadalafil appears to produce the same level of efficacy. Note that daily dosing trials generally used lower doses than did on demand trials.

Lifestyle modifications

Trials of sildenafil and avanafil used only on demand dosing. Data from trials that evaluated men from the general ED population are below. Tadalafil was the only medication for which there were substantial on demand vs. daily dosing studies. Most AEs follow a dose-response pattern such that men in active treatment arms reported statistically significantly higher rates of AEs than did men in placebo arms and the percentage of men reporting a particular AE increased as dose increases. Read more about these treatments below and talk with your urologist to find the right impotence treatment for you. Erectile dysfunction (ED), formerly termed impotence, is defined as "the inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance" or "the consistent or recurrent inability to attain and/or maintain penile erection sufficient for sexual satisfaction". [1] Although some cases, particularly in younger men, may primarily reflect psychological concerns, in many cases ED results from organic disease—notably, cardiovascular disease, diabetes mellitus, hyperlipidemia, and hypertension. [2] Thus, ED may serve as a marker for medical conditions in need of treatment.

• Lifestyle modifications are often the first step in ED treatment plans.
• Vacuum devices are non-invasive options suitable for many men.
• Pharmacological treatments should be used under medical supervision.
• Psychological support can address performance anxiety and emotional distress.
• Priapism is a potential side effect of some ED treatments; seek medical help if it occurs.
• Combining therapies might increase effectiveness for certain patients.
• Regular follow-up with healthcare providers ensures optimal management.

[1] Regardless of the cause, however, ED can have negative effects on patients' self-esteem, relationships, and overall quality of life. The first step in the management of ED is a thorough history that includes the following: A physical examination is necessary for every patient, emphasizing the genitourinary, vascular, and neurologic systems.

• PDE5i plus testosterone
• Lifestyle changes plus pills
• Vacuum pump plus pills
• Psychological counseling plus meds
• Multimodal treatment plans
• Personalized medicine approach
• Combining treatments for better results
• Managing multiple conditions
• Drug interaction checks
• Holistic health strategies
• Adjusting combination therapy

A focused examination entails evaluation of the following: Presence of the epididymis and vas deferens Abnormalities of the penis (eg, hypospadias, Peyronie plaques) There is a strong correlation between hypertension and ED. There is also a correlation between benign prostatic hyperplasia and ED, though the causality is unclear. Laboratory testing for ED depends on information gathered during the interview; it is necessary for most patients, although not for all. Evaluation of hormonal status (testosterone, serum hormone–binding globulin, luteinizing hormone [LH], prolactin, thyroid-stimulating hormone [TSH]) – Note that the American College of Physicians (ACP) does not recommend for or against routine use of hormonal blood tests or hormonal treatment in ED patients Evaluation of hormonal status (testosterone, serum hormone–binding globulin, luteinizing hormone [LH], prolactin, thyroid-stimulating hormone [TSH]) – Note that the American College of Physicians (ACP) does not recommend for or against routine use of hormonal blood tests or hormonal treatment in ED patients Screening blood studies (hemoglobin A1c, serum chemistry panel, lipid profile) Screening blood studies (hemoglobin A1c, serum chemistry panel, lipid profile) Prostate-specific antigen levels, if the patient is a candidate for prostate cancer screening (controversial) Prostate-specific antigen levels, if the patient is a candidate for prostate cancer screening (controversial) Functional tests that may be helpful include the following: Direct injection of prostaglandin E1 (PGE1; alprostadil) into the corpora cavernosa (see the image below) Direct injection of prostaglandin E1 (PGE1; alprostadil) into the corpora cavernosa (see the image below) Nocturnal penile tumescence testing – Once frequently performed, this is rarely used in current practice, though it can be helpful when the diagnosis is in doubt Nocturnal penile tumescence testing – Once frequently performed, this is rarely used in current practice, though it can be helpful when the diagnosis is in doubt Formal neurologic testing – Not needed in the vast majority of ED patients, though it may offer some benefit to patients with a history of central nervous system problems, peripheral neuropathy, diabetes, or penile sensory deficit Formal neurologic testing – Not needed in the vast majority of ED patients, though it may offer some benefit to patients with a history of central nervous system problems, peripheral neuropathy, diabetes, or penile sensory deficit Imaging studies are not commonly warranted, except in situations where pelvic trauma has been sustained or surgery performed.